Despite the promise of immune checkpoint therapies, treatment-resistant cancers remain a stubborn frontier, making it difficult to predict treatment responsiveness and optimize treatment protocols. A ...
Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR) ...
Captain T Cell GmbH has successfully closed an equity financing round to support its T-cell receptor (TCR) T-cell therapies for solid tumors. The company’s autologous lead program, CTC-127, is a ...
A new automated process for engineering tumor-targeting T cells could help accelerate personalized cancer treatments—while easing the physical toll on patients. Richard C. Koya, MD, PhD, who directs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results